Showing results (2041-2050 of 5,702) with videos related to

Sort By:
Pageof 571
The Oncologist|February 14, 2007
Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer--a review of the literatureAntónio Araújo, Ricardo Ribeiro, Isabel Azevedo, et al.
The Oncologist|November 18, 2006
Chronomodulated irinotecan, oxaliplatin, and leucovorin-modulated 5-Fluorouracil as ambulatory salvage therapy in patients with irinotecan- and oxaliplatin-resistant metastatic colorectal cancerDany Gholam, Sylvie Giacchetti, Catherine Brézault-Bonnet, et al.
The Oncologist|November 18, 2006
Bone loss and fracture risk associated with cancer therapyTheresa A Guise
The Oncologist|December 9, 2008
Persistence, up to 18 months of follow-up, of epirubicin-induced myocardial dysfunction detected early by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markersGiovanni Mantovani, Clelia Madeddu, Christian Cadeddu, et al.
The Oncologist|April 7, 2009
The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicineJeffrey S Ross, Elzbieta A Slodkowska, W Fraser Symmans, et al.
The Oncologist|July 8, 2009
Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinomaSadhna R Vora, Hui Zheng, Zsofia K Stadler, et al.
The Oncologist|February 5, 2009
Potential treatment options after first-line chemotherapy for advanced NSCLC: maintenance treatment or early second-line?Cesare Gridelli, Paolo Maione, Antonio Rossi, et al.
The Oncologist|February 6, 2009
Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumorsMartin H Cohen, Ann Farrell, Robert Justice, et al.
The Oncologist|February 11, 2009
Early-stage gastric MALT lymphoma: is it a truly localized disease?Marina P Siakantaris, Gerassimos A Pangalis, Evangelia Dimitriadou, et al.
The Oncologist|February 18, 2009
The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studiesGiorgio Scagliotti, Nasser Hanna, Frank Fossella, et al.
Pageof 571